A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging

Inclusion Criteria:

- Histologically-documented high-risk endometrioid adenocarcinoma with no visible
residual disease, defined by the following criteria:

1. Surgical stage I disease with < 50 myometrial invasion and grade 3 tumor (IBG3)
with lymphovascular space involvement;

2. Surgical stage I disease with > 50% myometrial invasion and grade 2 or 3 tumor
(ICG2, ICG3);

3. Any surgical stage II disease (IIA, IIB);

4. Any surgical stage III disease (IIIA, IIIB, IIIC); and

5. Any surgical stage IV disease with no residual macroscopic tumor

- Surgical staging to include total abdominal hysterectomy, bilateral
salpingo-oophorectomy, peritoneal washings, and lymph node samplings as per standard
GOG criteria.

- Age > 18 years.

- ECOG performance status of < 2.

Exclusion Criteria:

- Patient has impairment of hepatic, renal or hematologic function as defined by the
following baseline laboratory values:

1. Serum SGOT and /or SGPT > 2.5 times the institutional upper limit of normal

2. Total serum bilirubin > 1.5 mg/dl

3. History of chronic or active hepatitis

4. Serum creatinine > 2.0 mg/dl

5. Platelets < 100,000/mm3

6. Absolute neutrophil count (ANC) < 1500/mm3

7. Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry).

- Patient has severe or uncontrolled concurrent medical disease (eg Un-controlled
diabetes, unstable angina, myocardial infarction within 6 months, congestive heart
failure, etc.)

- Patient with any prior chemotherapy or radiotherapy for pelvic malignancy.

- Patients with dementia or altered mental status that would prohibit the giving and
understanding of informed consent at the time of study entry.

- Patients with any history of cancer with the exception of non-melanoma skin cancer
are excluded if there is any evidence of other malignancy being present within the
past five years.